Scarica l'app Stockscreener
179.25
1.55%
-2.82
Dopo l'orario di chiusura:
179.00
-0.25
-0.14%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AXSM Giù?
Forum
Previsione
Precedente Chiudi:
$182.07
Aprire:
$182.55
Volume 24 ore:
982.67K
Relative Volume:
1.40
Capitalizzazione di mercato:
$9.39B
Reddito:
$708.24M
Utile/perdita netta:
$-188.30M
Rapporto P/E:
-47.94
EPS:
-3.7392
Flusso di cassa netto:
$-70.99M
1 W Prestazione:
-8.12%
1M Prestazione:
-14.61%
6M Prestazione:
+6.38%
1 anno Prestazione:
+49.45%
Intervallo 1D:
$175.46
$182.55
Intervallo di 1 settimana:
$175.46
$198.96
Portata 52W:
$117.30
$260.19
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Nome
Axsome Therapeutics Inc
Settore
Industria
Telefono
(212) 332-3241
Indirizzo
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Compare AXSM vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
179.25 | 10.22B | 708.24M | -188.30M | -70.99M | -3.7392 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-24 | Iniziato | Wolfe Research | Outperform |
| 2026-01-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-01 | Iniziato | B. Riley Securities | Buy |
| 2025-09-03 | Ripresa | Wells Fargo | Overweight |
| 2025-07-03 | Ripresa | Morgan Stanley | Overweight |
| 2025-06-03 | Iniziato | Oppenheimer | Outperform |
| 2025-04-07 | Iniziato | Jefferies | Buy |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-12-31 | Reiterato | Mizuho | Outperform |
| 2024-09-03 | Iniziato | Wells Fargo | Overweight |
| 2024-08-06 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-07-22 | Iniziato | Needham | Buy |
| 2024-04-29 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-03-19 | Iniziato | Robert W. Baird | Outperform |
| 2024-02-06 | Iniziato | UBS | Buy |
| 2024-01-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-12-13 | Iniziato | Citigroup | Buy |
| 2023-08-08 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-01-05 | Iniziato | Piper Sandler | Neutral |
| 2022-11-01 | Iniziato | Loop Capital | Buy |
| 2022-09-07 | Ripresa | Mizuho | Buy |
| 2021-08-10 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-10 | Iniziato | Berenberg | Buy |
| 2021-01-08 | Iniziato | Jefferies | Buy |
| 2020-12-16 | Iniziato | Mizuho | Buy |
| 2020-09-29 | Iniziato | BofA Securities | Underperform |
| 2020-09-10 | Iniziato | Morgan Stanley | Overweight |
| 2020-04-28 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-14 | Iniziato | Cowen | Outperform |
| 2019-12-30 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-17 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-16 | Reiterato | Guggenheim | Buy |
| 2019-10-16 | Iniziato | Guggenheim | Buy |
| 2019-09-18 | Iniziato | William Blair | Outperform |
| 2019-05-28 | Iniziato | SunTrust | Buy |
| 2019-05-23 | Reiterato | H.C. Wainwright | Buy |
| 2019-04-08 | Iniziato | SVB Leerink | Outperform |
| 2019-03-15 | Reiterato | H.C. Wainwright | Buy |
| 2016-10-03 | Ripresa | Brean Capital | Buy |
| 2015-12-15 | Iniziato | Cantor Fitzgerald | Buy |
| 2015-12-14 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Axsome Therapeutics Inc Borsa (AXSM) Ultime notizie
Axsome Therapeutics, Inc. (AXSM) Stock Price, News, Quote & History - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO), ClearPoint Neuro (CLPT) and Axsome Therapeutics (AXSM) - theglobeandmail.com
Responsive Playbooks and the AXSM Inflection - Stock Traders Daily
Deutsche Bank Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Cuts Target Price to $267 - Moomoo
EBITDA per share of Axsome Therapeutics, Inc. – HAN:19X - TradingView
Axsome Therapeutics Is Maintained at Buy by Deutsche Bank - Moomoo
Axsome Therapeutics options flow shows heavy put skew ahead of binary catalyst - Investing.com
Axsome Therapeutics (NASDAQ:AXSM) Shares Down 5.4% on Analyst Downgrade - MarketBeat
Axsome Therapeutics slides as investors weigh launch execution and policy risks - Quiver Quantitative
Axsome Therapeutics, Inc. Revenue Breakdown – HAN:19X - TradingView
Axsome Therapeutics (NASDAQ:AXSM) Price Target Cut to $267.00 by Analysts at Deutsche Bank Aktiengesellschaft - MarketBeat
Deutsche Bank Lowers Price Target on Axsome Therapeutics to $267 From $280, Keeps Buy Rating - marketscreener.com
Axsome Therapeutics Is Maintained at Equal-Weight by Morgan Stanley - moomoo.com
AXSM Maintains Rating by Morgan Stanley -- Price Target Lowered to $247 - GuruFocus
Morgan Stanley Maintains Axsome Therapeutics(AXSM.US) With Hold Rating, Maintains Target Price $251 - Moomoo
H.C. Wainwright reiterates Axsome stock Buy rating at $290 target - Investing.com
H.C. Wainwright reiterates Axsome stock Buy rating at $290 target By Investing.com - Investing.com Canada
AXSOME THERAPEUTICS, INC. : TRUIST SECURITIES ASSUMES COVERAGE WITH BUY RATING; TARGET PRICE $285 VS $200 - webull.com
$100 Invested In Axsome Therapeutics 10 Years Ago Would Be Worth This Much Today - Benzinga
AXSM Stock Price and Chart — NASDAQ:AXSM - TradingView
10 Health Care Stocks Whale Activity In Today’s Session - benzinga.com
Truist Securities maintains Buy rating on Axsome Therapeutics, $285 price target - TradingView
Truist Raises Price Target on Axsome Therapeutics to $285 From $200, Keeps Buy Rating - marketscreener.com
Truist initiates Axsome stock coverage with buy rating on growth By Investing.com - Investing.com Nigeria
Truist initiates Axsome stock coverage with buy rating on growth - Investing.com
Axsome Therapeutics’ Q4 Numbers Beat Wall Street Expectations: Analyst Sees Over 23% Upside For Stock - Stocktwits
Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer’s Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer’s Day - The Manila Times
Axsome Therapeutics Announces Results of the Shared Goals - GlobeNewswire
Axsome Therapeutics, Inc. (AXSM) Stock Analysis: Promising 37% Upside Potential Amidst Strong Buy Ratings - DirectorsTalk Interviews
Axsome Sees AUVELITY Prescriptions Accelerate as Alzheimer’s Launch Gains Traction - MarketBeat
Axsome Therapeutics (AXSM) Stock Looks Undervalued As Its 5 Year 7x Run Continues - Yahoo Finance
Is Axsome Therapeutics’ (AXSM) New CNS Data Enough To Reinforce Its Neuropsychiatric Portfolio Story? - Yahoo Finance
Axsome Therapeutics Highlights Auvelity Growth, Pipeline Progress at H.C. Wainwright Conference - MarketBeat
Bank of America Corp DE Acquires Shares of 452,491 Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics (AXSM) Reported New Clinical Data In Depression And Alzheimer’s Agitation - Yahoo Finance
Analysts Think Axsome Therapeutics Stock Could Soar 35% Over the Next 12 Months. Is the Stock a No-Brainer Buy? - Yahoo Finance
Axsome Therapeutics (NASDAQ:AXSM) Receives "Overweight" Rating from Piper Sandler - MarketBeat
Axsome Therapeutics Price Target Maintained With a $258.00/Share by Piper Sandler - Moomoo
Piper Sandler reiterates Overweight rating on Axsome Therapeutics, $258 price target - TradingView
Axsome's Auvelity Launch Shows Early Strength in Alzheimer's Agitation, RBC Says - Yahoo Finance
Is Axsome Therapeutics a Buy on the Dip? - Yahoo Finance
Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026 - The Manila Times
Axsome Therapeutics Presents Ten Posters Exemplifying its - GlobeNewswire
Baird Financial Group Inc. Acquires New Holdings in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Ten posters cover depression, Alzheimer’s agitation and narcolepsy - Stock Titan
Axsome Therapeutics at H.C. Wainwright conference: growth broadens By Investing.com - Investing.com South Africa
Axsome Therapeutics at H.C. Wainwright conference: growth broadens - Investing.com
Engineers Gate Manager LP Has $2.74 Million Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics at Morgan Stanley conference: growth, pipeline and cash - Investing.com
Axsome Therapeutics, Inc. (AXSM) Investor Outlook: A Biotech Stock with 29% Upside and Robust Growth Potential - DirectorsTalk Interviews
About Axsome Therapeutics, Inc. rStock - Coinbase
Axsome Therapeutics Inc Azioni (AXSM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Axsome Therapeutics Inc Azioni (AXSM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Jacobson Mark L. | Chief Operating Officer |
Sep 03 '26 |
Sale |
208.65 |
10,000 |
2,086,500 |
0 |
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):